Pfizer and BioNTech, which are evaluating at least four experimental coronavirus vaccines in clinical studies, would supply the U.S. government with at least 100 million doses.
Pfizer and BioNTech, which are evaluating at least four experimental coronavirus vaccines in clinical studies, would supply the U.S. government with at least 100 million doses.